

2015

Senate Bill 486 Evaluation Team  
CONSUMER REPORT CARD



**SUMMARY:**

The legislatively mandated deadline for report submission was July 1, 2015. There were 29 plans submitted to the State of California which posted them on their website for public consumption. These plans were read and graded by an evaluation team, scoring each plan based on published consumer criteria. There were:

- Four "A" grade plans;
- Two “B” grade plans;
- Two "C" grade plan;
- Nineteen "F" grade plans.
- In addition, fifteen “F/Incomplete” grade plans were given for those manufacturers who did not submit plans by the legislatively mandated deadline of July 1 or did not submit plans whatsoever.

At least fourteen manufacturers resubmitted or retyped their 2011, 2012, 2013 or 2014 plans verbatim and those are indicated with an asterisk (\*). Plans that were submitted **after** the legislatively mandated July 1 deadline are marked with a (∞).

<u>Manufacturer</u>	<u>Score</u>	<u>Grade</u>
Alexion∞	10	F
Amgen	90	A
AstraZeneca	14	F
Bayer*	21	F
Biogen	80	B
Bristol Meyers Squibb*		
Orencia	80	B
Other drugs	0	F
Drugs in trial	43	F
CSL Behring*	2	F
Dr. Reddy’s Lab*	9	F
Eli Lilly & Co.*	13	F
EMD Serono*	93	A
Genentech/Roche*	46	F
GlaxoSmithKline	42	C
Grifols, Inc.	15	F
Janssen Biotech, Inc.*	94	A
JHP*	3	F
Kaleo		I
Merck *	32	F
Novartis		
Signifor	75	C
Cosentyx	90	A
Perrigo*	5	F
Pfizer	25	F
Sandoz*	3	F
Sanofi-Aventis*	47	F
Shire∞	3	F
Teva	20	F
UCB, Inc.* ∞	17	F

THE FOLLOWING DRUG  
MANUFACTURERS ARE IN  
VIOLATION OF STATE LAW DUE TO  
THE FACT THAT THEY **DID NOT**  
**SUBMIT** ANY PLANS TO THE STATE IN  
2014 YET MAKE HOME INJECTABLE  
MEDICATION SUBJECT TO SB 486:

<b><u>Manufacturer</u></b>	<b><u>Grade</u></b>
Biovitrium (no plan on file since law went into effect in 2010)	F
Baxter (last plan on file: 2012, authored in 2010)	F
Dey Pharmaceuticals (last plan on file: 2011)	F
Eisai (last plan on file: 2014)	F
Ferring Pharmaceuticals (last submitted in 2011)	F
Hospira (last plan on file: 2011- claim they are not subject to SB 486)	F
InterMune (last plan on file: 2011)	F
Ipsen (last plan on file: 2011)	F
Kadmon (last plan on file: 2013)	F
NPS (last plan on file: 2013)	F
Novo Nordisk (last plan on file: 2011)	F
Mallinckrodt (Questcor) Pharmaceuticals (no plan on file since law went into effect in 2010)	F
Salix (last plan on file: 2012)	F
Viro (last plan on file: 2013)	F
Zoegenix (no plan on file since law went into effect in 2010; manufacturer claims they have a proprietary “needle-fee” subcutaneous injection delivery system and aren’t subject to SB 486)	F